STOCK TITAN

Amyris Inc - AMRS STOCK NEWS

Welcome to our dedicated news page for Amyris (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on Amyris.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amyris's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amyris's position in the market.

Rhea-AI Summary
Amyris, Inc. has commenced voluntary Chapter 11 proceedings to restructure its business and improve its cost and capital structure. The company plans to exit its consumer brands and secure $190 million in financing to support day-to-day operations. The restructuring aims to focus on R&D and the development of sustainable ingredients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-80.75%
Tags
none
-
Rhea-AI Summary
Amyris, a synthetic biotechnology company, announced the resignation of John Melo as President & CEO and the appointment of Han Kieftenbeld as Interim CEO. The company also announced a global reduction in force as part of its cost reduction targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
-
Rhea-AI Summary
Amyris, Inc. announces engagement of PwC for a transformation program to improve cost and capital structure. The company aims to reduce costs by approximately $250 million and simplify its business portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.07%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
-
Rhea-AI Summary
Amyris, Inc. (Nasdaq: AMRS) announced Q1 2023 financial results. Core revenue of $56.1 million exceeded guidance by 12%. Cash operating expense down 4% compared to Q1 2022 and down 24% versus Q4 2022. Completed strategic partnership with Givaudan for $200 million upfront cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences earnings
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.92%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
conferences earnings
Amyris Inc

Nasdaq:AMRS

AMRS Rankings

AMRS Stock Data

Petroleum Refineries
Manufacturing
Link
US
Emeryville

About AMRS

amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. the company is delivering its no compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. more information about the company is available at www.amyris.com.